Menopause and nutraceuticals: functional ingredients for each phase.

The international market for women’s menopausal health supplements is now worth more than $600 million globally, growing at more than 7 percent annually. In Europe, demand is driven by a generation of women aged 45 to 60 who are looking for non hormonal, natural, science — backed solutions – and willing to pay for well-formulated products. It’s not a trend: it’s a structural demand that brand owners are beginning to seriously guard.

What changes as estrogen declines

Menopause is defined by the permanent cessation of menstruation, resulting from the depletion of ovarian follicles and reduced production of estrogen and progesterone. Estrogen decline affects not only the reproductive sphere: estrogen has receptors in almost every tissue in the body — skin, bone, central nervous system, mucous membranes, cardiovascular system. Their reduction produces widespread and overlapping effects, which manifest themselves with different intensity from woman to woman.

The most common symptoms are grouped into three areas: vasomotor symptoms — hot flashes and night sweats, present in 70–80% of perimenopausal women; urogenital atrophy symptoms — vaginal dryness, dyspareunia, mucous membrane irritation; and systemic symptoms — sleep disturbances, mood changes, perceived cognitive decline, changes in body composition with increased visceral fat and reduced muscle mass.

Parallel to acute symptoms, long-term effects develop that impact bone health — with accelerated loss of bone mineral density in the first years after menopause — and cardiovascular health, where estrogen played a protective role that is progressively diminished.

Marine collagen: skin, bone and connective tissue

Decreased estrogen accelerates the decline in Collagen synthesis — already physiologically declining by about 1–2% per year after age 25. In the first five years after menopause, there is an estimated 30% loss of skin Collagen, with visible consequences on skin elasticity, thickness, and hydration. At the same time, Type I Collagen in bone decreases, contributing to postmenopausal osteoporosis.

Supplementation with hydrolyzed Marine Collagen – particularly small peptides (di- and tri-peptides) with high bioavailability — has shown in clinical studies an improvement in skin elasticity, hydration, and reduction of surface wrinkles, with effects documented after 8–12 weeks of intake. The association with Vitamin C — an indispensable cofactor for endogenous Collagen synthesis — and with Hyaluronic Acid amplifies the effect on maintaining tissue hydration.

Omega-7: the mucosal support the market was looking for

Mucosal dryness is one of the most common and least discussed symptoms of menopause — often experienced with embarrassment, rarely brought to the forefront of product communication. Yet it affects quality of life in a direct and significant way: vaginal dryness, irritation, dry eye syndrome, oral dryness are all expressions of the same mechanism — the reduction in the ability of mucous membranes to maintain their natural moisture in the absence of estrogen support.

Omega-7 from sea buckthorn — palmitooleic acid extracted from the pulp of Hippophae rhamnoides — s now the nutraceutical ingredient with the most specific clinical evidence on this symptom. A randomized controlled trial published in Maturitas documented an objective improvement in the integrity of the vaginal epithelium in postmenopausal women, with effects on dry eye as well. This is not a marginal result: it is an answer to a real need that most menopause products ignore.

Magnesium: sleep, nervous system and bone health

Magnesium is among the minerals that most directly address the needs of menopausal women — for multiple and converging reasons. Sleep disturbances are among the most disabling symptoms of this phase: Magnesium, particularly in Bisglycinate and Glycerophosphate forms, supports sleep quality through its action on GABA receptors and regulation of nocturnal cortisol. The nervous system under pressure — from stress, insomnia, hormonal changes — benefits from Magnesium’s calmingespecific action on neuromuscular transmission.

On the bone front, Magnesium is a structural component of the hydroxyapatite crystal and a cofactor of Vitamin D metabolism enzymes-an especially relevant role at a stage when bone health is under pressure. The combination of Magnesium + Vitamin D + Vitamin K2 is now considered the formulation standard for supporting bone health in postmenopausal women.

Ashwagandha: stress management in transition

The climacteric is a phase of profound readjustment, not only hormonal but also psychological. Anxiety, irritability, feelings of loss of control, decreased resistance to daily stress-these are experiences that many women describe as more destabilizing than the hot flashes themselves. Ashwagandha — with its documented action on reducing cortisol and balancing the autonomic nervous system — fits into this context as a key adaptogen.

Clinical studies conducted specifically in perimenopausal women show significant reductions in stress symptoms and improvements in sleep quality, with a favorable tolerability profile in validated doses (300–600 mg/day of standardized extract). It should be remembered that ashwagandha is not recommended during pregnancy and that the European regulatory framework on this plant is under review: those who formulate products for the EU market must monitor the evolving guidance of the competent authorities.

Building a formula: beyond the single ingredient

The real opportunity in the menopause segment is not the single ingredient — it is the multi-target formula. The perimenopausal woman rarely has only one symptom: she has hot flashes and insomnia, dryness and joint pain, variable mood and fatigue. A formulation that addresses multiple needs with synergistic ingredients and effective dosages is much more relevant than a single-ingredient Capsules.

Combinations with more scientific rationale for this segment include Marine Collagen + Hyaluronic Acid + Vitamin C for skin and connective tissues; Omega-7 + Vitamin A for mucous membranes; Magnesium + Vitamin D + Vitamin K2 for bones; and Ashwagandha + Magnesium for sleep and stress. The formulation challenge is to integrate these actives into a product with good compliance — format, flavor, dose size — and clear, credible communication.

If you are developing a women’s health line or would like to learn more about formulation possibilities for the menopause segment, we are available for a conversation.

The contents of this article are for informational purposes only and are not a substitute for medical advice. Postmenopausal women considering nutraceutical supplementation, particularly in the presence of ongoing drug therapies, are urged to consult their gynecologist or referring physician.